GlassScriptPhysician profile
Ravikumar Vasireddy
NPI 1043257413
$22,303.08
in general payments reported to CMS, 2019-2025
79 companies · $3,896 in 2025
The $3,896 reported for 2025 was more than what 79% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,522 · 2020: $1,928 · 2021: $2,077 · 2022: $2,645 · 2023: $3,400 · 2024: $5,834 · 2025: $3,896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $1,925 · Education: $1,115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,091.13 |
| Consulting Fee | $1,925.00 |
| Education | $1,114.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $2,114.67 | 2020-2025 | Brukinsa |
| Pfizer INC. | $1,462.60 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,390.63 | 2019-2025 | Kisqali, Piqray |
| Astrazeneca Pharmaceuticals LP | $1,381.84 | 2019-2025 | Enhertu, Calquence, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $1,364.91 | 2019-2025 | Opdivo |
| Pharmacyclics LLC, An Abbvie Company | $784.29 | 2020-2023 | Imbruvica, Epkinly |
| Amgen INC. | $777.64 | 2019-2023 | Xgeva, Vectibix, Nplate |
| Seagen INC. | $775.16 | 2019-2025 | Tukysa, Adcetris, Padcev |
| Janssen Biotech, INC. | $736.08 | 2019-2025 | Imbruvica, Darzalex, Tecvayli |
| Abbvie INC. | $690.38 | 2019-2025 | |
| Astellas Pharma US INC | $654.14 | 2019-2025 | Padcev, Xtandi, Vyloy |
| Eisai INC. | $621.71 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $566.50 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Takeda Pharmaceuticals U.S.A., INC. | $533.07 | 2019-2025 | Ninlaro, Iclusig, Alunbrig |
| Incyte Corporation | $532.07 | 2019-2025 | Monjuvi, Jakafi |
Show all 79 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $491.74 | 2019-2025 | |
| Celgene Corporation | $460.77 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Lilly USA, LLC | $455.13 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Genentech USA, INC. | $387.19 | 2019-2025 | Polivy, Tecentriq, Lunsumio |
| Genzyme Corporation | $377.92 | 2019-2025 | |
| Puma Biotechnology, INC. | $311.33 | 2021-2025 | Nerlynx |
| Gilead Sciences, INC. | $309.38 | 2021-2025 | Trodelvy |
| Array Biopharma INC | $290.25 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| Kyowa Kirin, INC. | $276.80 | 2019-2025 | Poteligeo |
| Karyopharm Therapeutics INC. | $268.19 | 2020-2025 | Xpovio |
| Regeneron Healthcare Solutions, INC. | $261.45 | 2019-2025 | Libtayo |
| Sobi, INC | $258.36 | 2022-2025 | |
| Daiichi Sankyo INC. | $234.09 | 2019-2025 | Enhertu, Datroway |
| Teva Pharmaceuticals USA, INC. | $191.49 | 2019-2020 | |
| Epizyme, INC. | $182.18 | 2020-2021 | |
| Pharmacosmos Therapeutics INC. | $178.95 | 2021-2024 | Monoferric, Cosela |
| Glaxosmithkline, LLC. | $163.07 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Aveo Pharmaceuticals, INC. | $149.80 | 2022-2025 | Fotivda |
| Exelixis INC. | $142.99 | 2019-2024 | Cabometyx |
| Sumitomo Pharma America, INC. | $141.14 | 2023-2024 | Orgovyx |
| Mirati Therapeutics, INC. | $140.91 | 2023-2024 | Krazati |
| Rigel Pharmaceuticals, INC. | $135.52 | 2022-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Accord Healthcare, INC. | $119.57 | 2024-2025 | |
| Intuitive Surgical, INC. | $106.30 | 2024 | |
| Myovant Sciences INC. | $105.78 | 2021-2022 | |
| Spectrum Pharmaceuticals INC. | $104.61 | 2023-2025 | Rolvedon |
| Caris Mpi, INC. | $103.15 | 2025 | Mi Cancer Seek |
| Stemline Therapeutics INC. | $85.01 | 2024-2025 | Orserdu |
| Ipsen Biopharmaceuticals, INC | $82.03 | 2019-2025 | Onivyde, Tazverik |
| Verastem, INC. | $78.58 | 2019 | |
| Ge Healthcare | $75.55 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.65 | 2020-2024 | Gilotrif |
| Emd Serono, INC. | $70.46 | 2019-2023 | Bavencio |
| Fennec Pharmaceuticals, INC. | $70.34 | 2024 | Pedmark |
| Tersera Therapeutics LLC | $69.23 | 2019 | |
| Adc Therapeutics America, INC. | $63.54 | 2024-2025 | |
| G1 Therapeutics, INC. | $62.66 | 2022-2023 | Cosela |
| Asd Specialty Healthcare, LLC | $60.27 | 2025 | |
| Cti Biopharma Corp. | $58.44 | 2022-2023 | Vonjo |
| Myriad Genetic Laboratories, INC. | $55.21 | 2021-2023 | Myrisk |
| Clovis Oncology, INC. | $54.33 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $50.78 | 2023-2024 | Odomzo, Yonsa |
| Dova Pharmaceuticals | $49.53 | 2020-2021 | |
| Tesaro, INC. | $43.91 | 2019 | |
| Coherus Oncology, INC. | $43.51 | 2020-2021 | |
| Dendreon Pharmaceuticals LLC | $42.69 | 2025 | Provenge |
| Foundation Medicine, INC. | $39.89 | 2019 | |
| Jazz Pharmaceuticals INC. | $36.70 | 2025 | |
| Springworks Therapeutics, INC. | $34.95 | 2025 | Ogsiveo |
| Beone Medicines USA, INC. | $25.58 | 2025 | Brukinsa |
| Fortovia Therapeutics, INC. | $23.52 | 2019 | |
| Geron Corporation | $23.40 | 2025 | Rytelo |
| Tempus Ai, INC | $20.53 | 2025 | Xt Cdx |
| Immunocore Limited | $18.41 | 2024 | Kimmtrak |
| Genmab U.S., INC. | $18.33 | 2025 | Tivdak |
| Acceleron Pharma, INC. | $18.32 | 2020 | |
| Amneal Pharmaceuticals LLC | $18.09 | 2025 | Alymsys |
| Taiho Oncology, INC. | $16.83 | 2019 | |
| Acrotech Biopharma INC. | $16.66 | 2023 | Beleodaq |
| Secura Bio, INC. | $15.83 | 2022 | |
| Pharmaessentia USA Corporation | $15.41 | 2025 | Besremi |
| Blue Earth Diagnostics | $13.97 | 2023 | |
| Alexion Pharmaceuticals, INC. | $12.79 | 2019 | |
| Kite Pharma, INC. | $12.40 | 2022 |
Drugs and devices associated with these payments
Brukinsa $2,100Imbruvica $1,372Epkinly $670Lenvima $511Ibrance $477Enhertu $368Darzalex $315Xofigo $287Nubeqa $287Tecvayli $278Talvey $278Keytruda $269Orgovyx $262Padcev $249Reblozyl $249Tukysa $244Doptelet $238Kisqali $229Braftovi $224Adcetris $220Xtandi $215Sarclisa $214Libtayo $205Scemblix $200Verzenio $198Jaypirca $198Mektovi $197Lorbrena $196Xalkori $196Opdivo $195Pluvicto $154Lynparza $147Elrexfio $145Krazati $141Ninlaro $140Monjuvi $135Fotivda $126Calquence $123Cabometyx $120Camcevi $120Polivy $112Trodelvy $107Da Vinci Surgical System $106Rolvedon $105Mi Cancer Seek $103Iclusig $103Rezlidhia $99.90Tavalisse $99.90Piqray $97.94Poteligeo $91.38Tecentriq $90.90Nerlynx $89.66Retevmo $89.36Monoferric $88.14Comirnaty $86.49Talzenna $86.31Xpovio $85.41Orserdu $85.01Alunbrig $81.17Pedmark $70.34Lunsumio $66.06Tasigna $64.38Cosela $64.09Jakafi $63.94Columvi $60.28Onivyde $57.01Venclexta $55.80Paxlovid $53.63Yonsa $50.78Odomzo $50.78Nplate $50.67Xgeva $50.67Vectibix $50.67Elitek $50.66Ojjaara $46.92Provenge $42.69Vonjo $41.69Kyprolis $40.83Fabhalta $40.34Lutathera $36.67Vyloy $36.29Bosulif $35.08Phesgo $33.53Zejula $29.82Jemperli $29.82Gilotrif $27.81Datroway $27.50Myrisk $26.39Keytruda Qlex $25.98Rytelo $23.40Imfinzi $21.84Zynlonta $21.73Welireg $21.57Bavencio $21.53Gavreto $21.01Fruzaqla $20.67Xt Cdx $20.53Ziihera $19.28Itovebi $18.58Tecentriq Hybreza $18.58
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravikumar Vasireddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.